{
    "hands_on_practices": [
        {
            "introduction": "In clinical practice, distinguishing posterior scleritis from its mimics is a common diagnostic challenge. This exercise will guide you through the application of Bayes' theorem to quantify how a specific finding—the classic T-sign on B-scan ultrasound—updates your diagnostic certainty. Mastering this skill  is fundamental to practicing evidence-based medicine, allowing you to move from clinical suspicion to a formal, defensible post-test probability.",
            "id": "4713677",
            "problem": "A 34-year-old immunocompetent patient presents with acute periocular pain, decreased vision, and posterior segment findings suggestive of either posterior scleritis (PS) or retinal vasculitis (RV). Brightness mode ultrasonography (B-scan) reveals a classic T-sign. From high-quality diagnostic studies, the positive likelihood ratio (LR+) of a T-sign for PS is $LR_+ = 8$. Based on the clinical context and local epidemiology, your pretest probability for PS is $0.25$. Using Bayes’ theorem, and starting from the fundamental definitions of probability, odds, and likelihood ratios, compute the post-test probability of PS after a positive T-sign. Express your answer as a decimal probability (no percent sign). Round your answer to $4$ significant figures. Then, in your reasoning (not in the final numeric answer), succinctly interpret whether this post-test probability meaningfully shifts diagnostic weighting toward PS over isolated RV in this scenario, assuming test independence and applicability of the reported $LR_+$ to this patient population.",
            "solution": "The problem statement is assessed to be valid. It is scientifically grounded in the principles of clinical epidemiology and diagnostic testing, well-posed with sufficient information for a unique solution, and objective in its phrasing.\n\nWe are tasked with calculating the post-test probability of posterior scleritis (PS) after a positive diagnostic test finding. Let $D$ be the event that the patient has posterior scleritis, and let $T$ be the event of a positive test result (in this case, observing a T-sign on a B-scan ultrasound).\n\nThe given information is:\n1.  The pretest probability of PS: $P(D) = 0.25$.\n2.  The positive likelihood ratio for the T-sign test for PS: $LR_{+} = 8$.\n\nThe problem requires a solution derived from fundamental definitions. We begin with the concept of odds. The odds of an event $A$ are defined as the ratio of the probability that the event occurs to the probability that it does not occur:\n$$\n\\text{Odds}(A) = \\frac{P(A)}{P(A^c)} = \\frac{P(A)}{1 - P(A)}\n$$\nUsing this definition, we first convert the given pretest probability into pretest odds:\n$$\n\\text{Pretest Odds}(D) = \\frac{P(D)}{1 - P(D)} = \\frac{0.25}{1 - 0.25} = \\frac{0.25}{0.75} = \\frac{1}{3}\n$$\n\nNext, we use the definition of the positive likelihood ratio, $LR_{+}$. The $LR_{+}$ quantifies how much a positive test result increases the odds of having the disease. It is defined as the ratio of the probability of a positive test in a person with the disease (sensitivity) to the probability of a positive test in a person without the disease ($1$ minus specificity):\n$$\nLR_{+} = \\frac{P(T|D)}{P(T|D^c)}\n$$\nBayes' theorem provides a method to update our belief (probability) in light of new evidence. In its odds form, the theorem states that the post-test odds are the product of the pretest odds and the likelihood ratio. We can derive this relationship as follows. The post-test odds of disease given a positive test are:\n$$\n\\text{Post-test Odds}(D|T) = \\frac{P(D|T)}{P(D^c|T)}\n$$\nAccording to Bayes' theorem, $P(D|T) = \\frac{P(T|D)P(D)}{P(T)}$ and $P(D^c|T) = \\frac{P(T|D^c)P(D^c)}{P(T)}$. Substituting these into the odds equation:\n$$\n\\text{Post-test Odds}(D|T) = \\frac{\\frac{P(T|D)P(D)}{P(T)}}{\\frac{P(T|D^c)P(D^c)}{P(T)}} = \\frac{P(T|D)P(D)}{P(T|D^c)P(D^c)}\n$$\nRearranging the terms gives:\n$$\n\\text{Post-test Odds}(D|T) = \\left(\\frac{P(T|D)}{P(T|D^c)}\\right) \\left(\\frac{P(D)}{P(D^c)}\\right) = LR_{+} \\times \\text{Pretest Odds}(D)\n$$\nWe can now calculate the post-test odds of PS using the given values:\n$$\n\\text{Post-test Odds}(D|T) = 8 \\times \\frac{1}{3} = \\frac{8}{3}\n$$\n\nFinally, we convert these post-test odds back to a probability. The formula to convert odds back to probability is:\n$$\nP(A) = \\frac{\\text{Odds}(A)}{1 + \\text{Odds}(A)}\n$$\nApplying this to our post-test odds:\n$$\nP(D|T) = \\frac{\\frac{8}{3}}{1 + \\frac{8}{3}} = \\frac{\\frac{8}{3}}{\\frac{3}{3} + \\frac{8}{3}} = \\frac{\\frac{8}{3}}{\\frac{11}{3}} = \\frac{8}{11}\n$$\nThe problem requires the answer as a decimal rounded to $4$ significant figures.\n$$\nP(D|T) = \\frac{8}{11} \\approx 0.727272...\n$$\nRounding to $4$ significant figures, we get $0.7273$.\n\nRegarding the interpretation requested in the prompt: The pretest probability of PS was $P(D)=0.25$, meaning there was a $1$ in $4$ chance of the patient having PS based on the initial clinical picture. The competing diagnosis, isolated retinal vasculitis (or other causes), had a complementary probability of $0.75$. The finding of a T-sign, with a moderately high $LR_{+}$ of $8$, has shifted the post-test probability to $P(D|T) \\approx 0.7273$. This increase from $25\\%$ to approximately $73\\%$ is a substantial and clinically meaningful change. Before the test, the alternative diagnosis was three times more likely than PS. After the positive test, PS is now almost three times more likely than the alternative diagnosis (odds of $8/3$, or approximately $2.67$ to $1$). This result decisively shifts the diagnostic weight towards posterior scleritis, making it the leading diagnosis and guiding subsequent management.",
            "answer": "$$\\boxed{0.7273}$$"
        },
        {
            "introduction": "Once a differential diagnosis is formed, advanced imaging is crucial for confirming the diagnosis and assessing the extent of vascular compromise. This problem  challenges you to compare fluorescein angiography (FA) and optical coherence tomography angiography (OCTA) from first principles. By understanding the physics and physiological basis of each modality, you will learn to critically interpret their findings, recognize their unique artifacts, and judiciously select the best tool to evaluate inflammation, ischemia, and leakage.",
            "id": "4713651",
            "problem": "A patient with posterior scleritis and concomitant active retinal vasculitis presents with decreased vision and deep ocular pain. Clinical examination reveals venous sheathing, perivenular hemorrhages, and shallow exudative retinal detachment in the posterior pole. The clinician orders fluorescein angiography (FA; fluorescein angiography) and optical coherence tomography angiography (OCTA; optical coherence tomography angiography) to assess ischemia and inflammatory activity. Using first principles of image formation and retinal vascular physiology, determine which statements most accurately compare FA and OCTA for detecting nonperfusion and leakage in this setting, and explain why OCTA cannot directly visualize dye leakage while FA can.\n\nChoose all that apply.\n\nA. Optical coherence tomography angiography cannot directly depict dye leakage because it detects motion contrast from intravascular erythrocytes via interscan decorrelation of the coherent backscatter signal; extravascular fluid is static and contains no exogenous fluorophore, whereas fluorescein angiography visualizes dynamic extravasation of sodium fluorescein into tissues, producing hyperfluorescence that increases over time.\n\nB. Compared with fluorescein angiography in acute retinal vasculitis, current clinical optical coherence tomography angiography is more sensitive for peripheral retinal nonperfusion because its field of view routinely exceeds $100$ degrees without montage.\n\nC. In posterior scleritis with exudative retinal detachment, optical coherence tomography angiography can artifactually exaggerate choriocapillaris flow deficits due to signal attenuation and segmentation errors beneath subretinal fluid, leading to overestimation of nonperfusion.\n\nD. In active retinal vasculitis, late-phase fluorescein leakage from inflamed venules can obscure adjacent capillary detail, leading to potential underestimation of capillary dropout on fluorescein angiography unless early frames are analyzed.\n\nE. Optical coherence tomography angiography quantifies leakage by computing the increase in decorrelation amplitude in the extravascular space on late acquisitions.\n\nF. In posterior scleritis, choroidal leakage on fluorescein angiography must always correspond to confluent choriocapillaris flow voids on optical coherence tomography angiography.",
            "solution": "Begin from image formation principles and vascular physiology. Fluorescein angiography (FA) uses an exogenous fluorophore, sodium fluorescein, injected intravenously. When excited by blue light, the dye emits green fluorescence. The dynamic distribution of dye within the vascular lumen and its extravasation through a disrupted inner blood–retina barrier or inflamed vessel wall produces time-dependent patterns of hyperfluorescence and hypofluorescence. Leakage is defined operationally as progressive increase in intensity and area of hyperfluorescence over time due to dye accumulating in extravascular spaces.\n\nOptical coherence tomography angiography (OCTA) is based on low-coherence interferometry of near-infrared light. OCTA detects blood flow by computing motion contrast, typically via interscan decorrelation of the complex-valued OCT signal across repeated B-scans. The key physical premise is that moving scatterers (erythrocytes) induce temporal fluctuations in the backscattered speckle pattern, while static tissues produce relatively stable signals. Therefore, OCTA encodes the presence of flow above a velocity and signal-to-noise threshold, generating angiograms without dye. Because OCTA does not use an exogenous fluorophore and relies on motion of intravascular cells, extravascular fluid or dye does not generate angiographic signal unless there is motion of scatterers.\n\nNonperfusion refers to absence of functional capillary blood flow. On FA, nonperfusion is inferred where intravascular dye fails to fill capillary networks, but interpretation can be complicated by blocking (hemorrhage), staining, and leakage that obscures borders, especially in late phases. Early frames can better delineate capillary beds before extensive leakage. On OCTA, nonperfusion is inferred as flow voids where decorrelation is below threshold; however, artifacts from attenuation (hemorrhage, edema, subretinal fluid), projection, segmentation errors, and limited field of view can mimic or exaggerate flow voids. In posterior scleritis with exudative retinal detachment, subretinal fluid and thickened tissues attenuate the OCT signal and alter segmentation, particularly at the level of the choriocapillaris, which can lead to overestimation of nonperfusion. Field of view constraints also limit OCTA coverage of the far periphery relative to ultra-widefield FA.\n\nEvaluate options:\n\nA. This statement directly contrasts the physics. OCTA detects motion contrast of intravascular erythrocytes via interscan decorrelation of a coherent backscatter signal. Extravascular dye lacks moving scatterers and OCTA has no exogenous fluorophore; thus, it cannot show leakage as progressive hyperfluorescence. FA, by contrast, visualizes dynamic extravasation because sodium fluorescein diffuses into tissues when barriers are disrupted, increasing fluorescence over time. This is consistent with first principles and is Correct.\n\nB. This claims OCTA is more sensitive for peripheral nonperfusion due to field of view routinely exceeding $100$ degrees. In practice, clinical OCTA fields are typically limited to a few millimeters on the retina (for example, $3 \\times 3$ mm to $12 \\times 12$ mm scans), and even widefield or montaged OCTA does not routinely exceed the ultra-widefield capabilities of FA (often up to approximately $200$ degrees). Thus, OCTA is not generally more sensitive for peripheral nonperfusion by virtue of field of view; FA, especially ultra-widefield FA, remains superior for far-peripheral assessment. This is Incorrect.\n\nC. Posterior scleritis often produces exudative retinal detachment and choroidal thickening. Subretinal fluid and thickened tissues attenuate the OCT signal and can cause segmentation errors at the choriocapillaris slab, generating apparent flow voids that overestimate nonperfusion. This follows from the attenuation of backscattered signal reducing decorrelation confidence beneath fluid and from algorithmic slab misplacement. This is Correct.\n\nD. In retinal vasculitis, late-phase FA often shows venular leakage and diffuse capillary leakage, which can obscure fine capillary detail and the margins of nonperfused zones. Unless early-phase frames are used, the extent of capillary dropout can be underestimated due to veiling glare from leakage and staining. This statement aligns with FA interpretation principles and is Correct.\n\nE. OCTA does not quantify leakage by increased decorrelation in extravascular spaces; extravascular dye does not produce flow. While decorrelation amplitude can vary with flow dynamics, there is no mechanism to directly visualize dye accumulation outside vessels on OCTA. Therefore, this is Incorrect.\n\nF. Choroidal leakage on FA reflects hyperpermeability and barrier disruption, not necessarily frank flow loss. It does not have to correspond to confluent choriocapillaris flow voids on OCTA; flow can be preserved despite leakage, and OCTA signals can be affected by attenuation and segmentation issues. Hence, a one-to-one correspondence is not required. This is Incorrect.\n\nTherefore, the correct options are A, C, and D.",
            "answer": "$$\\boxed{ACD}$$"
        },
        {
            "introduction": "Effective management hinges on translating diagnostic insights into a coherent therapeutic plan. This practice problem  places you in the role of a clinician deciding how to treat cystoid macular edema ($CME$), a common and vision-threatening complication of retinal vasculitis. You will synthesize principles of pathophysiology and pharmacology to determine when to use anti-VEGF agents versus systemic anti-inflammatory therapy, reflecting the nuanced, evidence-based reasoning required for expert patient care.",
            "id": "4713712",
            "problem": "A clinician is deciding between intravitreal Vascular Endothelial Growth Factor (VEGF) inhibition and systemic anti-inflammatory therapy to treat cystoid macular edema in the setting of retinal vasculitis and, in some patients, posterior scleritis. Use the following foundational principles as the starting point for your reasoning: (i) the inner blood–retina barrier is formed by tight junctions of retinal capillary endothelial cells; its permeability increases with both inflammatory cytokines and VEGF; (ii) VEGF production increases with retinal hypoxia via hypoxia-inducible pathways and promotes angiogenesis and vascular permeability; (iii) glucocorticoids reduce transcription of pro-inflammatory cytokines and stabilize endothelial barrier function, while steroid-sparing immunosuppressants reduce immune activation sustaining vasculitis; (iv) intravitreal anti-VEGF agents have short intraocular residence but potently and selectively suppress VEGF-mediated leakage and neovascularization; (v) infectious vasculitis requires pathogen-directed therapy as the primary intervention; (vi) posterior scleritis is a scleral inflammatory disease often showing a “T-sign” on ultrasound and responds to systemic anti-inflammatory therapy rather than anti-VEGF. Based only on these principles and on clinically realistic scenarios, select all statements that correctly identify conditions under which anti-VEGF is beneficial for inflammatory cystoid macular edema in vasculitis, versus when systemic corticosteroids or immunosuppressants are superior.\n\nA. In a vasculitis patient with clinically quiescent intraocular inflammation on systemic immunomodulatory therapy, but with extensive peripheral capillary nonperfusion on widefield fluorescein angiography (FA) and new preretinal neovascularization with center-involving cystoid macular edema, intravitreal VEGF inhibitor is expected to provide significant short-term anatomic benefit and is appropriate in conjunction with ischemia-directed therapy such as panretinal photocoagulation (PRP).\n\nB. In active noninfectious retinal vasculitis with diffuse perivascular leakage on FA and cystoid macular edema without macular ischemia, systemic corticosteroids with steroid-sparing immunosuppression are superior to anti-VEGF monotherapy for sustained visual and anatomic control.\n\nC. In posterior scleritis with exudative retinal detachment and cystoid macular edema, primary intravitreal VEGF inhibitor monotherapy is preferred over systemic anti-inflammatory therapy.\n\nD. In infectious retinal vasculitis from tuberculosis with cystoid macular edema, high-dose systemic corticosteroids alone are first-line, and VEGF inhibitors are contraindicated in any setting.\n\nE. In a steroid responder with intraocular pressure (IOP) elevation to $30\\,\\mathrm{mmHg}$ and persistent low-grade cystoid macular edema despite adequate control of intraocular inflammation on nonsteroidal immunosuppression, an intravitreal VEGF inhibitor can be used as an adjunct to limit corticosteroid exposure.\n\nSelect all that apply.",
            "solution": "The user has provided a problem asking to evaluate the appropriateness of different therapeutic strategies for cystoid macular edema (CME) in the context of retinal vasculitis and posterior scleritis, based on a given set of six foundational principles.\n\n**Problem Statement Validation**\n\nFirst, I will validate the problem statement.\n\n**Step 1: Extract Givens**\n\nThe foundational principles provided are:\n(i) The inner blood–retina barrier is formed by tight junctions of retinal capillary endothelial cells; its permeability increases with both inflammatory cytokines and Vascular Endothelial Growth Factor (VEGF).\n(ii) VEGF production increases with retinal hypoxia via hypoxia-inducible pathways and promotes angiogenesis and vascular permeability.\n(iii) Glucocorticoids reduce transcription of pro-inflammatory cytokines and stabilize endothelial barrier function, while steroid-sparing immunosuppressants reduce immune activation sustaining vasculitis.\n(iv) Intravitreal anti-VEGF agents have short intraocular residence but potently and selectively suppress VEGF-mediated leakage and neovascularization.\n(v) Infectious vasculitis requires pathogen-directed therapy as the primary intervention.\n(vi) Posterior scleritis is a scleral inflammatory disease often showing a “T-sign” on ultrasound and responds to systemic anti-inflammatory therapy rather than anti-VEGF.\n\n**Step 2: Validate Using Extracted Givens**\n\nI will now assess the problem statement based on these givens.\n- **Scientifically Grounded:** The principles provided are fundamental and well-established concepts in ophthalmology, immunology, and pharmacology. They accurately describe the pathophysiology of the blood-retina barrier, the roles of VEGF and inflammation, and the mechanisms of action for the major therapeutic classes mentioned. The problem is scientifically sound.\n- **Well-Posed:** The problem provides a set of axioms (the principles) and asks for lógico-deductive evaluation of several statements. This structure is well-posed, leading to a determinable set of correct answers based on the provided information.\n- **Objective:** The principles and the question are stated in precise, objective, and unbiased language, free of subjective claims.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. It is scientifically grounded, well-posed, and objective. There are no contradictions, ambiguities, or missing information that would preclude a rigorous analysis. I will now proceed to evaluate each option based on the provided principles.\n\n**Option-by-Option Analysis**\n\n**A. In a vasculitis patient with clinically quiescent intraocular inflammation on systemic immunomodulatory therapy, but with extensive peripheral capillary nonperfusion on widefield fluorescein angiography (FA) and new preretinal neovascularization with center-involving cystoid macular edema, intravitreal VEGF inhibitor is expected to provide significant short-term anatomic benefit and is appropriate in conjunction with ischemia-directed therapy such as panretinal photocoagulation (PRP).**\n\n*   **Analysis:** The scenario describes a situation where the primary inflammatory component of vasculitis is \"quiescent\" due to systemic therapy. However, a major sequela, \"extensive peripheral capillary nonperfusion\" (ischemia), has occurred.\n*   According to principle (ii), retinal hypoxia (ischemia) leads to increased VEGF production. This VEGF, in turn, promotes \"neovascularization\" and \"vascular permeability,\" explaining the new preretinal neovascularization and the cystoid macular edema (CME). This aligns with principle (i), which states VEGF increases the permeability of the inner blood-retina barrier.\n*   According to principle (iv), intravitreal anti-VEGF agents \"potently and selectively suppress VEGF-mediated leakage and neovascularization.\" Therefore, administering an anti-VEGF agent would directly counteract the pathological effects of the high VEGF levels, providing \"significant short-term anatomic benefit\" by reducing CME and causing regression of neovascularization.\n*   The statement also correctly notes that this should be done \"in conjunction with ischemia-directed therapy such as panretinal photocoagulation (PRP).\" This is logical because anti-VEGF treats the consequences of ischemia, while PRP treats the underlying cause (the ischemic retina that is producing VEGF). This combined approach is consistent with the principles.\n*   **Verdict:** **Correct**. The reasoning is sound and directly follows from principles (i), (ii), and (iv).\n\n**B. In active noninfectious retinal vasculitis with diffuse perivascular leakage on FA and cystoid macular edema without macular ischemia, systemic corticosteroids with steroid-sparing immunosuppression are superior to anti-VEGF monotherapy for sustained visual and anatomic control.**\n\n*   **Analysis:** The scenario is \"active noninfectious retinal vasculitis.\" The primary driver of pathology is inflammation.\n*   According to principle (i), barrier permeability and thus CME are caused by both \"inflammatory cytokines\" and \"VEGF.\" In active vasculitis, inflammatory cytokines are the primary instigators.\n*   According to principle (iii), systemic therapy with \"glucocorticoids\" and \"steroid-sparing immunosuppressants\" directly targets this root cause by reducing \"pro-inflammatory cytokines\" and overall \"immune activation.\" This approach is designed for \"sustained\" control.\n*   According to principle (iv), anti-VEGF agents are \"selective\" for VEGF and have a \"short intraocular residence.\" Using anti-VEGF as monotherapy would only address the VEGF component of the leakage, leaving the primary inflammatory cytokine-driven process untreated. This would likely lead to recurrence once the short-acting drug wears off.\n*   Therefore, a therapy targeting the fundamental inflammatory disease process (systemic therapy) is logically superior for achieving \"sustained\" control compared to a therapy that only targets a single, downstream mediator (anti-VEGF monotherapy).\n*   **Verdict:** **Correct**. The statement correctly prioritizes treating the underlying inflammatory disease for long-term control, which is consistent with principles (i), (iii), and (iv).\n\n**C. In posterior scleritis with exudative retinal detachment and cystoid macular edema, primary intravitreal VEGF inhibitor monotherapy is preferred over systemic anti-inflammatory therapy.**\n\n*   **Analysis:** The diagnosis is \"posterior scleritis\". The complications include exudative retinal detachment and CME.\n*   Principle (vi) states explicitly that posterior scleritis \"responds to systemic anti-inflammatory therapy rather than anti-VEGF.\"\n*   The statement proposes the exact opposite: that anti-VEGF monotherapy is \"preferred over\" systemic therapy. This is a direct contradiction of a foundational principle provided in the problem.\n*   **Verdict:** **Incorrect**. This statement directly violates principle (vi).\n\n**D. In infectious retinal vasculitis from tuberculosis with cystoid macular edema, high-dose systemic corticosteroids alone are first-line, and VEGF inhibitors are contraindicated in any setting.**\n\n*   **Analysis:** The diagnosis is \"infectious retinal vasculitis from tuberculosis.\"\n*   Principle (v) states that \"Infectious vasculitis requires pathogen-directed therapy as the primary intervention.\"\n*   The statement proposes \"high-dose systemic corticosteroids alone are first-line.\" Using immunosuppressants like corticosteroids alone in the face of an active infection like tuberculosis without concurrent anti-infective treatment can lead to unchecked proliferation of the pathogen and disastrous systemic consequences. This action violates principle (v). The first-line therapy must be anti-tuberculous medication.\n*   The second part of the statement, that VEGF inhibitors are \"contraindicated in any setting,\" is an overly strong and not necessarily correct universal claim, but the first part of the statement is definitively incorrect based on the provided principles.\n*   **Verdict:** **Incorrect**. The proposed first-line therapy is a direct and dangerous violation of principle (v).\n\n**E. In a steroid responder with intraocular pressure (IOP) elevation to $30\\,\\mathrm{mmHg}$ and persistent low-grade cystoid macular edema despite adequate control of intraocular inflammation on nonsteroidal immunosuppression, an intravitreal VEGF inhibitor can be used as an adjunct to limit corticosteroid exposure.**\n\n*   **Analysis:** The scenario describes a complex situation: The underlying inflammation is \"adequately control[led],\" but there is \"persistent low-grade\" CME. A significant treatment-limiting side effect of corticosteroids, IOP elevation to $30\\,\\mathrm{mmHg}$, is present. The goal is to \"limit corticosteroid exposure.\"\n*   Since the inflammation is mostly controlled, the persistent CME might be driven by a non-cytokine-mediated pathway. Principle (i) notes that both cytokines and VEGF cause leakage. Principle (ii) explains VEGF can be upregulated by chronic, low-grade hypoxia secondary to prior vascular damage. It is plausible that the residual CME is predominantly VEGF-mediated.\n*   Principle (iv) states that anti-VEGF agents potently suppress VEGF-mediated leakage. Administering an intravitreal VEGF inhibitor would directly target this residual CME.\n*   Using anti-VEGF as an \"adjunct\" would allow for reduction or cessation of corticosteroids, thus mitigating the dangerous IOP elevation. This therapeutic strategy logically applies the principles to solve a specific clinical problem (managing a complication and a side effect simultaneously).\n*   **Verdict:** **Correct**. This represents a rational use of an adjunctive therapy to manage a specific pathological manifestation (VEGF-mediated CME) in order to avoid the side effects of another necessary therapy, which is consistent with principles (i), (ii), and (iv).",
            "answer": "$$\\boxed{ABE}$$"
        }
    ]
}